Latest Breaking News On - Altum pharmaceuticals inst - Page 1 : comparemela.com

The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.

Bristol myers squibbBristol myers squibb medarexDaniel morgenszternDivision of oncologyWashington university school of medicineVeterans administration lung studyAltum pharmaceuticals instAbbott laboratoriesMedical oncologyWashington university schoolArcus biosciencesLilly medicalAltum pharmaceuticalsArtcus biosciencesArray biopharmaBoehringer ingelheim